The study will evaluate 40 patients with inecalcitol comparing 20 patients with placebo.
In the trial, inecalcitol will be administered orally at four milligrams per day for 16 weeks.
The one-year trial is expected to begin in the last quarter of 2011.
The company has been granted a zero interest loan of EUR650,000 by OSEO, to cover 45% of the overall costs of the study.
Hybrigenics Clinical R&D head Jean-François Dufour-Lamartinie said the study could extend the therapeutic potential of inecalcitol to non-cancerous proliferative diseases.